SCHEMBL23740368

SCHEMBL23740368

c1ccc(-c2nc(-c3ccc4ccccc4c3)nc(-c3ccc4c(c3)oc3cc(-n5c6c7ccccc7ccc6c6ccc7ccccc7c65)ccc34)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
TP53 P04637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A1 P04798 4/20 0.36
CYP1B1 Q16678 3/20 0.36
PDPK1 O15530 5/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
MAPK9 P45984 3/20 0.34
MAPK10 P53779 3/20 0.34
MAPK8 P45983 1/20 0.34
PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23740529 0.93 CYP1A2 (0.36) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL23740486 0.92 CYP1A2 (0.36) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL23740611 0.90 CYP1A1 (0.35) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL24104886 0.90 PDPK1 (0.33) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL21862834 0.89 PDPK1 (0.32) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL23740687 0.88 KDM4E (0.34) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL23740485 0.88 PGR (0.33) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL24362125 0.88 SMN1; SMN2 (0.41) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL21862962 0.86 KDM4E (0.34) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL24363445 0.85 ABCG2 (0.35) CYP1A2SMN1; SMN2KDM4EALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395263-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE LT MATERIALS CO., LTD. (KR) 2021-12-23 US disclosed
EP-3862353-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE LT Materials Co., Ltd. (KR) 2021-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395263-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE ODC1, AOX1, CYP1B1 CYP1A2 16/4885SMN1; SMN2 3657/4885KDM4E 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.